May 2008
Volume 49, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2008
Topically Administered Mecamylamine (ATG-3) Penetrates to the Retina-Choroid and Reduces Laser-Induced Choroidal Neovascularization in C57BL/6J Mice
Author Affiliations & Notes
  • K. M. Kengatharan
    Preclinical R & D, CoMentis Inc, South San Francisco, California
  • R. Lima e Silva
    Wilmer Eye Institute, Johns Hopkins University, Baltimore, Maryland
  • J. Yu
    Preclinical R & D, CoMentis Inc, South San Francisco, California
  • J. Hey
    Preclinical R & D, CoMentis Inc, South San Francisco, California
  • J. P. Cooke
    Cardiovascular Medicine, Stanford University, Stanford, California
  • P. Campochiaro
    Wilmer Eye Institute, Johns Hopkins University, Baltimore, Maryland
  • Footnotes
    Commercial Relationships  K.M. Kengatharan, CoMentis Inc, I; CoMentis Inc, E; CoMentis Inc, P; R. Lima e Silva, None; J. Yu, CoMentis Inc, E; J. Hey, CoMentis Inc, E; J.P. Cooke, CoMentis Inc, I; CoMentis Inc, P; CoMentis Inc, R; P. Campochiaro, CoMentis Inc, F; CoMentis Inc, C.
  • Footnotes
    Support  None.
Investigative Ophthalmology & Visual Science May 2008, Vol.49, 3424. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      K. M. Kengatharan, R. Lima e Silva, J. Yu, J. Hey, J. P. Cooke, P. Campochiaro; Topically Administered Mecamylamine (ATG-3) Penetrates to the Retina-Choroid and Reduces Laser-Induced Choroidal Neovascularization in C57BL/6J Mice. Invest. Ophthalmol. Vis. Sci. 2008;49(13):3424. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract
 
Purpose:
 

To assess the efficacy and ocular bioavailability of topically administered mecamylamine (ATG-3, MEC), a non-selective nicotinic acetylcholine receptor (nAChR) antagonist with anti-angiogenic properties in a murine model of choroidal neovascularization (CNV).

 
Methods:
 

In a masked experiment, 5 to 6 week-old female C57BL/6J mice were divided into 6 groups (9-10 animals/group); (1) vehicle b.i.d, (2) 0.1% MEC b.i.d and, (3) 1% MEC b.i.d; all sacrificed at 7d post injury, and (4) vehicle b.i.d, (5) 0.1% MEC b.i.d and, (3) 1% MEC b.i.d; all sacrificed at 14d post injury. At day 0, laser-photocoagulation-induced rupture of Bruch’s membrane was used to generate CNV (as per Lima e Silva, et al 2005) and treatment started. At 7d or 14d, mice were anesthetized and perfused with fluorescein-labeled dextran (2 x 106 average MW) and choroidal flat mounts were prepared. These were examined by fluorescence microscopy, images digitized and the area of each CNV lesion analyzed using image analysis software. In a separate experiment, mice were administered topically 3% MEC b.i.d, for 2 days and sacrificed on day 3 and the retina-choroid, plasma and red-blood cells (RBC) isolated for measurement of MEC by LC-MS-MS at 1, 3, 6 and 24h post single dose. Data are expressed as mean ± SEM. Statistical comparisons were made using one-way ANOVA with Bonferroni’s correction.

 
Results:
 

MEC given topically achieved micromolar level penetration into the retina-choroid (RC) with close to assay BLOQ levels observed in the plasma (P) or RBC at all time points assessed (ratios at 1hr; RC:P = 418.6; RC:RBC 565.5; P:RBC=1.3). These results suggest that topical delivery of MEC leads to significant penetration to the retina-choroid and reduction in CNV induced by laser-injury.  

 
Conclusions:
 

Topically delivered MEC, a non-selective nACh receptor antagonist, penetrates to the retina-choroid and reduces CNV in a mouse model of neovascular AMD.Reference: Lima e Silva R, et al., (2005). IOVS, Sep;46(9):3323-30.

 
Keywords: age-related macular degeneration • choroid: neovascularization • neovascularization 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×